ACADIA Pharmaceuticals Inc. (ACAD) Bears Frown at FDA-Induced Lift

A big-time drug development has ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) sitting higher

Nov 2, 2015 at 2:39 PM
facebook X logo linkedin


Back in mid-July, drugmaker ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) jumped to an all-time high of $51.99. Since then, though, the shares have cooled, and have underperformed the S&P 500 Index (SPX) by 18.5 percentage points in the past two months. The stock is starting to rebound today, gaining 14.8% to trade at $39.97, after the Food and Drug Administration (FDA) granted the company's nuplazid treatment for Parkinson's disease priority review status. 

Looking elsewhere, put volume on ACAD is running at 17 times the average afternoon pace. The stock's most popular strike is the November 38 put, though it looks to be seeing sell-to-open activity. In other words, traders are betting on the shares to continue trading above $38 through the close on Friday, Nov. 20, when front-month options expire. 

Taking a step back, it's common to see traders buying to open ACAD puts. According to data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the security's 10-day put/call volume ratio stands at 1.03, higher than 99% of all readings taken in the previous year. In other words, traders have been buying to open puts over calls at a faster-than-usual pace of late -- suggesting they may not be too pleased with today's bullish price movement.

ACAD also boasts high short interest levels. Over 18% of the equity's float is sold short, and would take over 12 days to repurchase, at normal daily volumes. 

Analysts, meanwhile, have taken a strong bullish tone on the stock. Seven of eight covering brokerage firms say ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a "buy" or better, with not a single "sell" to be found. Looking ahead, the company is slated to reported earnings this Thursday evening.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI